

1 **Detection of Circulating Tumor-specific DNA Methylation Markers in the Blood of**
2 **Patients with Pituitary Tumors.**

3 Michael Wells^{1,2}, Karam P. Asmaro^{1,2}, Thais S. Sabedot^{1,2}, Tathiane M. Malta^{1,2},
4 Maritza S. Mosella^{1,2}, Kevin Nelson¹, James Snyder^{1,2}, Ana deCarvalho¹, Abir
5 Mukherjee³, Dhananjay Chitale³, Adam Robin¹, Mark Rosenblum¹, Thomas
6 Mikkelsen¹, Laila M. Poisson⁴, Ian Y. Lee¹, Tobias Walbert¹, Arti Bhan⁶, Steven
7 Kalkanis¹, Jack Rock¹, Houtan Noushmehr^{1,2}, Ana Valeria Castro^{1,2*}

8 ¹Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health
9 System, Detroit, MI, USA

10 ²Department of Neurosurgery, Omics Laboratory, Henry Ford Health System, Detroit,
11 MI, USA

12 ³Department of Pathology, Henry Ford Health System, Detroit, MI, USA

13 ⁴Department of Biostatistics, Henry Ford Health System, Detroit, MI, USA

14 ⁵Department of Radiology, Henry Ford Health System, Detroit, MI, USA

15 ⁶Department of Endocrinology, Henry Ford Health System, Detroit, MI, USA

16 ***Corresponding author**

17 Ana Valeria B. Castro, MD, PhD

18 Department of Neurosurgery

19 Hermelin Brain Tumor Center; Henry Ford Health System

20 2799 West Grand Blvd, E&R 3096

21 Detroit, MI, 48202

22 acastro1@hfhs.org

23

24 **Abstract**

25 Genome-wide DNA methylation aberrations are pervasive and associated with
26 clinicopathological features across pituitary tumors (PT) subtypes. The feasibility to detect
27 CpG methylation abnormalities in circulating cell-free DNA (cfDNA) has been reported in
28 central nervous system tumors other than PT. Here, we aimed to profile and identify
29 methylome-based signatures in the serum of patients harboring PT (n=13). Our analysis
30 indicated that serum cfDNA methylome from patients with PT are distinct from the
31 counterparts in patients with other tumors (gliomas, meningiomas, colorectal carcinomas,
32 n=134) and nontumor conditions (n=4). Furthermore, the serum methylome patterns
33 across PT was associated with functional status and adenohypophyseal cell lineage PT
34 subtypes, recapitulating epigenetic features reported in PT-tissue. A machine learning
35 algorithm using serum PT-specific signatures generated a score that distinguished PT
36 from non-PT conditions with 100% accuracy in our validation set. These preliminary
37 results underpin the potential clinical application of a liquid biopsy-based DNA methylation
38 profiling as a noninvasive approach to identify clinically relevant epigenetic markers that
39 can be used in the management of PT.

40

41 **Word count:**

42 Title: 15

43 Abstract: 154

44 Main Text: 2,934

45 Methods: 1,272

46 References: 53

47

48 **Introduction**

49 Liquid biopsy (LB) is a method used to detect molecular elements (e.g., DNA, RNA,
50 etc.) shed by tumors in biofluids (blood, cerebrospinal fluid etc). Circulating cell-free DNA
51 (cfDNA), specifically the tumor DNA fraction (ctDNA), is thought to originate from cellular
52 death (apoptosis and necrosis) or secretion from live cells, especially from proliferative
53 tissues or tumors ¹⁻⁵. Blood-based LB has emerged as a reliable and a minimally invasive
54 approach to identify clinically relevant molecular biomarkers from several tumor origins,
55 including from central nervous system (CNS) neoplasms ⁵⁻⁸.

56 In contrast to CNS tumors that are shielded by the blood-brain barrier, the pituitary
57 gland presents an anatomical structure that facilitates the spillage of tumor cellular
58 material into the bloodstream, i.e. a fenestrated pituitary portal system and/or an access
59 to the cavernous system. This structural advantage creates an opportunity to profile
60 tumor-specific molecular features of material released from these tumors potentially
61 suitable for clinicopathological application ^{9,10}. Indeed, the feasibility to detect and
62 sequence somatic gene variants in ctDNA has recently been reported in PT ¹; however,
63 the detection sensitivity of this approach was low in these tumors ¹. The paucity of genetic
64 alterations in the pathogenesis of PT such as recurrent somatic mutations may have
65 contributed to these results ¹¹⁻¹⁵. In contrast, genome-wide methylation abnormalities
66 detected in the tissue are knowingly pervasive across PT subtypes ^{13,16-23}. Additionally,
67 DNA methylome patterns are tissue- and tumor-specific providing an opportunity to
68 predict the tissue of origin of the tumor through DNA methylation profiling ^{5,20,24,25}. In fact,
69 many studies showed that specific methylome patterns detected in the tissue
70 distinguished PT from other CNS tumors and defined discrete methylation subtypes

71 among different CNS tumors ^{20,26,27}. Additionally, methylation markers presented
72 diagnostic, prognostic and predictive applications in CNS tumors ^{20,26,27}. The feasibility of
73 detecting these tissue- or tumor-specific methylation signatures using a liquid biopsy
74 approach is an emerging field that has not been reported in PT to date.

75 In this study, we profiled the serum cfDNA methylome derived from patients with
76 PT or other tumors and nontumor conditions. We identify unique methylation signatures
77 in the serum associated with clinicopathological features specific to PT. This proof-of-
78 concept study paves the way for the potential clinical application of a liquid biopsy as a
79 noninvasive approach to identify and assess relevant epigenetic markers that may be
80 useful in the management of patients with PT.

81 **Results**

82 **Characterization of pituitary cell-free DNA methylome**

83 **cfDNA quantification**

84 Total extracted serum cfDNA quantity, normalized to the genomic size (ng/ml, see
85 Methods), were not significantly different from controls (mean±SD, 59.3±134.2 vs 5±5.0
86 ng/ml, respectively; p=.14) or in relation to functional or invasion status in PT
87 **(Supplemental Figure 1A).**

88 **Deconvolution**

89 The deconvolution of the serum cfDNA methylome showed that patients harboring PT
90 had higher proportion of bulk pituitary gland signatures compared to the control serum
91 and other CNS conditions (3% higher, p = .05)**(Supplemental Figure 1B; Supplemental**
92 **Table 2).**

93 **Methylome analysis**

94 The genome-wide mean methylation landscape of the serum cfDNA from patients with
95 PT and non-PT conditions (gliomas, meningiomas, colorectal carcinomas and nontumor
96 conditions) showed that PT segregated into a hypomethylated and a hypermethylated
97 cluster; the latter, shared similar CpG methylation degree with the serum methylome from
98 patients with glioma, meningioma, colorectal cancer and nontumor controls (**Figure 1A**
99 **and 1B**).

100 Conducting a supervised analysis between PT and non-PT serum specimens and
101 selecting probes that shared similarities with the matching PT tissue (**Supplemental**
102 **Figure 1D, left**), we identified 46 differentially methylated probes (DMP), namely Pituitary
103 Tumors-specific Epigenetic-Liquid Biopsy (PeLB) probes, that significantly distinguished
104 both groups (**Figure 1B**) and distinguished two subgroups across PT (hyper and
105 hypomethylated) (**Figure 1C**),

106 The two methylation clusters were associated with distinct clinicopathological
107 status, i.e. the hypermethylated cluster was predominantly composed of nonfunctioning,
108 mainly encompassed by SF1 lineage and null cell tumors and the hypomethylated with
109 functioning PT mostly comprised of Pit1-lineage tumors (**Figure 1 C**). As an exception,
110 one lactotroph adenoma/Pit1-lineage segregated with nonfunctioning PT, despite being
111 clinically classified as functioning, and a functioning Tpit1-lineage tumor clustered with
112 nonfunctioning tumors. These results recapitulate the findings in their matching tissue
113 (**Supplemental Figure 1E**).

114 **cfDNA methylome from patients with PT pituitary-specific epigenetic signatures**
115 **distinct from other pathological conditions.**

116 Overlapped with tumor tissues, PeLB probes clustered with PT tissue and significantly
117 separated PT from other CNS tumor-tissue, confirming PeLB-specificity to PT in an
118 independent cohort (**Figure 1D**). Taking this feature into account, we developed and
119 cross-validated a score derived from a machine learning (ML) model (repeated 5000
120 times), namely the PeLB score, to predict whether a serum specimen originates from a
121 patient with PT or a non-PT condition (**Figures 1E-F**). Pituitary-derived serum methylome
122 samples carried the highest values of PeLB score (71-99%), whereas the serum of non-
123 PT tumors carried the lowest values (0-45%) (**Figure F**). The evaluation of the model in
124 the validation sample set showed that the model performed with an accuracy of 100%,
125 taking into account a 50% PeLB cutoff.

126 We also defined serum-based methylation signatures (n=70) accounting for the
127 functional/lineage status of PT (nonfunctioning vs functioning PT) ($p < .01$, differential
128 mean methylation $>.2$, FDR $< .26$), we named functioning-PeLB (Func-PeLB)(**Figures**
129 **2A, Supplemental Figure 1D, right**). Harnessing the methylome from matching tissue
130 and publicly available data reporting on the functional status of PT, we observed that a
131 subset of the Func-PeLB probes (overlapped with the 450K platform, used to profile the
132 tissue-methylome of those samples) (n=22 probes) (**Supplemental Figure 1D, right**),
133 also discriminated the two functional groups at the tissue and respective serum levels
134 (**Figure 2B-D**)

135 The CpG probes that distinguished the methylation clusters either in tissue
136 (n=5000) or serum (6000) were most frequently located in open sea regions (67% and
137 61%, respectively) and gene bodies (61 and 55%, respectively) (**Figure 1B,**
138 **Supplemental Table 2**).

139 **Discussion**

140 Methylome-derived signatures define molecular subtypes that are useful for the
141 diagnosis and prognostication across many tumors^{13,16–18,20,21,26–29}. Additionally,
142 genome-wide DNA methylation patterns are cell-specific either in healthy or tumor
143 specimens^{5,18,20,24,25,30–32}. The ability to detect methylation signatures and tumor-specific
144 abnormalities by the profiling of circulating cell-free DNA (cfDNA) in biofluids (liquid
145 biopsy), such as blood, has been useful for the early detection and surveillance of
146 malignant neoplasms^{5,33–35}. In relation to CNS tumors, our group has recently reported
147 on the feasibility to identify methylation-based markers in serum-derived cfDNA for the
148 diagnosis and prognostication of gliomas and meningiomas³⁶. Herein, we show that,
149 similar to malignant and other CNS tumors, PT releases tumor-related information in the
150 blood that allows the identification of clinically relevant methylation signatures specific to
151 patients with PT, namely PeLB probes (**Figure 1A-B; Supplemental Figure 1D**).
152 Capitalizing on the specificity of these probes, we used a machine learning approach to
153 generate the PeLB score (Figure 1D-E) to predict the presence of a pituitary tumor using
154 liquid biopsy. We showed that PeLB score performed with a 100% accuracy to predict
155 that serum was derived from patients with PT in our validation cohort (**Figure 1F**). These
156 results remain to be confirmed in an independent cohort of PT-derived, currently
157 unavailable.

158 In addition, distinct serum DNA methylation landscape, specifically PeLB probes,
159 defined two methylation groups that recapitulated the clinicopathological findings
160 displayed in their matching tissue as reported in other studies^{13,16–18,20,21} (**Figure 1C-D,**
161 **Supplemental Figure 1E**). These serum-derived clusters showed that the

162 hypermethylated group was enriched by nonfunctioning PT mainly originated from SF1
163 and Tpit cell lineages and the hypomethylated set mainly composed of functioning PT
164 mostly originated from Pit-1 cell lineages (**Figure 1C, Supplemental Figure 1D**). We
165 narrowed down to a subset of PeLB probes (Func-PeLB) that preserved the distinction
166 between both clusters in tumor-tissue specimens as well (**Figure 2C, Supplemental**
167 **Figure 1D**). Altogether, these results suggest that PT releases DNA methylation markers
168 in the serum that reflect clinicopathological features such as functional status and
169 adenohypophyseal lineage of these tumors. Confirmation of these findings in a larger and
170 more comprehensive cohort lay the groundwork to the application of PeLB probes as an
171 objective approach to classify PT according to cell-lineage as recommended by the 2017
172 WHO ³⁷.

173 Considering the prognostic value reported in glioma or meningiomas, we surveyed
174 serum-methylation markers specific to the invasion status of PT. Corroborating the
175 findings reported in the tissue, we found slight serum differences between invasive and
176 noninvasive groups (data not shown)^{13,16,17,21}. However, the association of tissue- or
177 serum-derived methylation groups with the criteria that better predict PT with higher risk
178 to progress or recur remains to be elucidated ^{13,18,38–43}.

179 The application of PeLB score is not intended to replace the standard approaches
180 to diagnose and classify PT which, in most of the cases, is satisfactorily performed by
181 clinical features, hormonal assessment in the blood/urine and on the imaging of the
182 pituitary gland ⁴⁴. However, these results provide evidence that serum cfDNA constitutes
183 a reliable source of clinically relevant tumor-specific epigenetic signatures in PT as
184 observed in other CNS tumors ³⁶. Potentially, the specificity of PeLB probes could be

185 helpful to distinguish PT from other rare primary or secondary sellar tumors whose
186 diagnosis by morphologic and immunohistochemical approaches may be challenging,
187 unavailable and/or inconclusive (e.g. craniopharyngioma variants, lymphoma, metastasis
188 etc) ^{5,34,45,46}.

189 In conclusion, our results indicate that similar to malignant tumors, PT releases
190 circulating tumor DNA that present specific methylation patterns, recapitulating molecular
191 features detected in PT-tissue (e.g. adenohipophyseal lineage-related). Serum from
192 patients with PT provides tumor-specific methylation signatures that allow the
193 classification of samples into PT subtypes or non-PT groups. Finally, our preliminary
194 results underpin the potential application of methylation profile in the serum-based liquid
195 biopsy as a noninvasive approach to assess clinically relevant epigenetic features useful
196 for clinical purposes in the management of patients (e.g. aggressiveness markers,
197 actionable markers to guide future clinical trials to treat aggressive, resistant or recurrent
198 PT etc).

199 **Methods**

200 **Patients** - We conducted a retrospective analysis of a cohort comprised of archival serum
201 and paired tissue (fresh-frozen) from 13 patients who underwent transsphenoidal surgery
202 for the resection of invasive (n=5) or noninvasive (n=8) macroadenomas of different
203 functional status and histological subtypes (9 nonfunctioning: 4 gonadotroph and 5 null
204 cell and 4 functioning: 2 lactotroph, 1 corticotroph and 1 mixed GH/PRL/TSH) (Table 1).
205 Criteria for invasiveness was based on Knosp grades 3-4 (n=4) or invasion of clivus (n=1)
206 ^{47,48}. MRI assessment for size, and invasiveness classification was blindly and
207 independently performed by two physicians from the Henry Ford Health System (HFHS)
208 (TA, KPA). HFHS Pathologists provided a comprehensive pathology report on
209 adenohipophyseal immunostaining, necrosis and quantification of markers of
210 proliferation (Ki-67, mitotic counts, p53). Control serum was obtained from patients
211 without PT (three epileptic patients and one with a nontumor condition). Control pituitary
212 tissue was obtained from non-neoplastic pituitary harvested at autopsy (FFPE). We also
213 generated serum methylome data from patients with glioma (n=114), meningiomas (n=6)
214 and other CNS conditions (brain metastasis, 1 brain colloid cyst, 6 brain radiation
215 necrosis) (Supplemental Table 2) The project was approved by the HFHS Institutional
216 Review Board (IRB# 10963) and patients consented to have their specimens used for
217 research purposes. Publicly available methylome data from colorectal carcinoma was
218 retrieved (CRC, n= 2 pooled samples) ⁴⁹.

219 **Serum collection and processing**

220 For the specimens originated from the HFHS, peripheral blood (15 mL) was drawn
221 from each subject at the time of surgery before the tumor excision (transphenoidal).

222 Serum sample was separated within 1 hour from collection by centrifugation at 1,300 x g
223 for 10 minutes at 20°C; aliquoted into up to five 2 mL cryovials and stored at -80°C until
224 processing. The methods for the publicly available data is described in their respective
225 manuscripts ⁴⁹

226 **DNA isolation, quantification, and DNA methylation data generation**

227 Tissue and serum DNA were extracted from 2.2-9.3mL aliquots of serum using the
228 Quick-cfDNA Serum & Plasma Kit according to the manufacturer's protocol (Zymo
229 Research - catalog # D4076). DNA concentration was measured with Qubit (Thermo
230 Fisher Scientific) /or with 4200 TapeStation (Agilent Technologies). The concentration of
231 cfDNA in the serum was calculated by dividing the total amount of cfDNA extracted by
232 the amount of serum used for extraction. We then converted the concentration of cfDNA
233 in the serum (ng/mL) into haploid genome equivalents/mL by multiplying by a factor of
234 303 (assuming the mass of a haploid genome 3.3 pg) ⁵⁰.

235 The extracted DNA (30-300 ng) was bisulfite-converted (Zymo EZ DNA
236 methylation Kit; Zymo Research) and profiled using an Illumina Human EPIC array
237 (HM850K), at the USC Epigenome Center, Keck School of Medicine, University of
238 Southern California, Los Angeles, California. The raw DNA methylation data reported in
239 this paper has been deposited to Mendeley Data at
240 <https://data.mendeley.com/datasets/cgrz6zztfg>.

241 **DNA methylation pre-processing**

242 Methylation array data was processed with the minfi package in R. The raw signal
243 intensities were extracted from the *.IDAT files and corrected for background
244 fluorescence intensities and red-green dye-bias using the function preprocessNoob as

245 described by Triche et al., 2013⁵¹. The beta-values were calculated as $(M/(M+U))$, in
246 which M and U refer to the (pre-processed) mean methylated and unmethylated probe
247 signal intensities, respectively. Measurements in which the fluorescent intensity was not
248 statistically significant above background signal (detection p value $> 10^{-16}$) were removed
249 from the data set. Before the analysis, we filtered out probes that were designed for
250 sequences with known polymorphisms or probes with poor mapping quality (complete list
251 of masked probes provided by Zhou et al.⁵²) and the X and Y chromosomes.

252 **Deconvolution**

253 We applied a previously described methodology⁵⁰ to deconvolute the relative
254 contribution of cell types to a given sample⁵⁰. We included methylation signatures from
255 cell lines, immune cells (B-cell, CD4T, CD8T, natural killer cells and white blood cells
256 (monocytes, neutrophils) and vascular endothelial cells⁵⁰ (Supplemental Table 2) For
257 lack of information related to methylation signatures from individual cells that comprise
258 the pituitary gland, we generated genome-wide methylation signatures from bulk non-
259 neoplastic pituitaries obtained from cadavers (unpublished data) and followed the steps
260 for defining the signatures as previously described⁵⁰. Briefly, we selected the 100 most
261 specific hypermethylated and hypomethylated CpG probes for each cell/tissue type of
262 interest. Using this signature, we applied a non-negative least squares method to
263 deconvolute our serum and tissue cohort using the standalone program provided by Moss
264 and colleagues⁵⁰. We then normalized the percentages generated by the standalone
265 program for each cell type/PT-tissue from 0 to 100 by serum.

266 **DNA methylation exploratory analysis (unsupervised analysis)**

267 In order to evaluate the DNA methylation profile in the serum from patients with
268 distinct tumor types and non-neoplastic brain diseases, we performed a genome-wide
269 Principal Component Analysis (PCA) across the samples (N=147) using the function
270 *prcomp* (version 3.6.0). Consensus clustering was determined by k-means clustering of
271 euclidean distance from the *ConsensusClusterPlus* (version 1.48.0) package.

272 **Supervised analysis**

273 We also performed an epigenome-wide differential analysis across the serum from
274 10 patients with PT and 105 with non-PT conditions patients (4 non-tumor, 114 glioma, 3
275 meningioma, 1 brain metastasis carcinoma, 1 colloid cyst, and 4 from other CNS necrotic
276 tumors). We used the Wilcoxon rank-sum test to identify differentially methylated probes
277 between two different pairs: PT vs non-PT and functioning vs nonfunctioning PT.

278 For the comparison between PT and non-PT, probes were considered differentially
279 methylated when the false discovery rate (FDR) was less than .001 and absolute value
280 of the difference of a pair of probe mean methylation between each group was greater
281 than 20%. To identify DMP in the serum that were tissue-specific, we calculated the
282 differences in DNA methylation between the matching serum and tissue, by patient. We
283 then selected probes with less than 5% difference between tissue and serum and
284 considered them tissue-specific.

285 To validate their PT-specificity, we overlapped PeLB probes with the DNA
286 methylome of an independent cohort consisting of pituitary-, glioma- and meningioma-
287 tissue (Figure 1D).

288 For the comparison between functioning and nonfunctioning, probes were
289 considered differentially methylated when the p-value was less than .01 and absolute

290 value of the difference of probe mean methylation between each group was greater than
291 20%.

292 **Random Forest**

293 We used a random forest machine-learning (ML) model for binary classification of
294 the specimens with the aim to classify available cfDNA methylation (from serum) derived
295 from patients with PT and non-PT (other neoplastic or non-neoplastic conditions:
296 meningioma, glioma and colorectal carcinoma and nontumor). We first randomly
297 allocated 20% of all samples for the validation set (n = 3 PT; n = 29 Non-PT) only analyzed
298 for the assessment of the prediction model accuracy. The remainder serum specimens
299 were used for the feature extraction or training of the random forest model. For developing
300 the model we randomly partitioned the remainder samples into a training (n = 8 PT; n =
301 84 Non-PT) and testing set (n = 2 PT; n = 21 Non-PT). We used the function *train*
302 (package *caret* version 6.0.82) in CRAN, with 5000 trees, and 10 fold cross validation to
303 generate our model. When testing the model, we used an output of 50% probability as a
304 cut-off for classification.

305 Based on this result, we adopted the default PeLB score cutoff value of 50 to
306 determine whether a patient had PT. We evaluated the performance of the prediction by
307 applying the ML model on the validation set.

308 **Probe annotation**

309 CpG probes were mapped to their CpG genomic location as CpG islands (CGI),
310 shores, shelves, and open sea regions as previously defined ⁵²⁻⁵⁵.

311 **Statistical analysis**

312 All processing and statistical analyses were done in R (3.6.1). Wilcoxon rank-sum test
313 and multiple testing adjustments (e.g. FDR) were used to identify differentially
314 methylated probes (DMP) as stated in the previous sections.

315 **Supplementary information**

316 **Acknowledgements**

317 The authors are grateful to the HFHS patients who consented to the usage of PT for
318 research purposes. We thank Nancy Takacs and Heather Mengel for their
319 administrative support; Kevin Nelson for the collection, handling and maintenance of the
320 tumor bank at the Hermelin Brain Tumor Center; Andrea Transou for tumor pathology
321 processing; Laura A. Hasselbach for DNA extraction; Daniel Weisenberger and team at
322 USC Epigenome Center for assistance with DNA methylation profiling (HFHS support);
323 Susan MacPhee for proofreading the manuscript.

324 **Funding**

325 This work was supported by the Henry Ford Health System, Department of
326 Neurosurgery, and the Hermelin Brain Tumor Center. MSM and MC are supported by
327 the São Paulo Research Foundation (FAPESP), Brazil (#16/11039-3; #17/10357-
328 4,#14/03989-6); AVC and KPA by Henry Ford Hospital (A30935, A30957; GME
329 202199); LMP, HN, AD, MW, and AM by the National Institutes of Health
330 (R01CA222146), HN, TSS, TMM, LMP, and AD are supported by the Department of
331 Defense (CA170278).

332 **Author contributions**

333 Overall concept and coordination of the study: AVC, JR, HN, KPA; retrieval of publicly
334 available molecular and clinical data: KPA, MW, AVC; Bioinformatic and statistical

335 analyses: MW, TSS, TMM, MSM, HN and input from LMP; HFHF cohort: pathology
336 review AM, DC; molecular data generation: TMM, AD; the manuscript was written by
337 AVC, HN, MW and intellectual contribution from JS, TM, SK, TW. All authors
338 contributed to the revision of the manuscript.

339 **Data availability**

340 The data is available under the accession code GSEXXXX. All the other data supporting
341 the findings of this study are available within the article and supplemental information
342 and from the corresponding author upon reasonable request.

343 **Competing interests**

344 The authors declare to have no competing interests.

345 **Footnotes**

346 These authors contributed equally as first authors: Michael Wells, Karam P. Asmaro,
347 Thais S. Sabedot, Tathiane M. Malta, and Maritza S. Mosella. These authors
348 contributed equally as senior authors: Houtan Noushmehr, Ana Valeria Castro

349 **Contributor information**

350 Ana Valeria Castro, Email: acastro1@hfhs.org
351 Houtan Noushmehr, Email: hnoush1@hfhs.org

352

353 **TABLE LEGENDS**

354 **Table 1-** Summary of clinicopathological features of patients included in this study.

355 **FIGURE LEGENDS**

356 **Figure 1: Genome-wide DNA methylation profile of pituitary serum cfDNA.**

357 Identification of tissue-specific probes that distinguish pituitary serum from non-pituitary
358 serum specimens (Pituitary-tumor specific Epigenetic Liquid-biopsy or PeLB probes).
359 (A) PCA of the mean methylation of pituitary tumors and non-pituitary tumors (glioma,
360 meningioma and colorectal carcinoma) and controls (nontumor conditions). (B)
361 Heatmap depicting the methylation levels of PeLB probes across the entire serum
362 cohort (n=107); (C) Heatmap highlights the methylation levels of PeLB probes across
363 pituitary samples and overlapping clinicopathological annotations such as functional and
364 invasion status, transcription factor-related adenohypophyseal cell lineage. (D) The t-
365 Distributed Stochastic Neighbor Embedding (t-SNE) plot depicts the overlap of PeLB
366 probes with the methylome of serum specimens from patients harboring pituitary tumors
367 and of the tissue methylome from PT and other CNS tumors (glioma, meningioma). (E)
368 Workflow of sample partitioning of serum cohort for training, testing, and validation used
369 in the random forest analysis to distinguish pituitary tumors from non-pituitary tumors
370 (colorectal carcinoma, glioma, meningiomas). Each test tube represents 10% of the
371 samples. (F) Boxplot of the PeLB score results from the validation set. The dotted line at
372 50% represents the cutoff used for classification into pituitary tumors and non-pituitary
373 samples.

374 **Figure 2: Supervised analysis to identify tissue-specific probes that distinguish**
375 **serum originated from functioning pituitary tumor from those from nonfunctioning**
376 **PT (Functioning Pituitary-tumor specific Epigenetic Liquid-biopsy-PeLB or Func-**
377 **PeLB).**

378 (A) Heatmap displays the methylation levels of the 70 Func-PeLB differentially methylated
379 probes (DMP) in the serum of nontumor and tumor pituitary specimens. (B) Heatmap
380 displays the 22 Func-PeLB probes that overlap with the 450K array in nontumor and
381 pituitary tumor tissue (C) PCA of pituitary tumor tissue from an independent cohort using
382 the 22 Func-PeLB probes showing that they segregate samples based on functional

383 status in both tissue and serum. (D) Box plots of serum (left) and tissue (right) mean
384 methylation for each PT (functioning and nonfunctioning) and nontumors samples.

385

386 **SUPPLEMENTAL INFORMATION**

387 **Supplemental Table 1** - (A) Distribution of the number of the most variant methylated
388 probes in the serum and in the pituitary tumor tissue according to their genomic context
389 and CpG location. (B) Distribution of the number of differentially methylated probes
390 (PeLB and Func-PeLB) according to their genomic context and CpG location.

391

392 **Supplemental Figure 1** - (A) Cell-free DNA concentration in the serum derived from
393 patients with nontumor and tumor conditions. (B) Cell-free DNA concentration in the
394 serum of patients with pituitary tumors (PT) according to function and invasion status.
395 (C) Deconvolution of serum in relation to cell composition from control or pituitary tumor
396 patients. (D) Workflow displaying the selection criteria of pituitary tumor- and
397 functioning-specific methylated probes from the supervised analysis between PT and
398 non-PT (right) and Functioning and nonfunctioning PT (left) in the serum. (E) Heatmap
399 displaying the genome-wide methylation profile across PT tissue-specimens.

400

401

402

403 Bibliography

- 404 1. Megnis, K. *et al.* Evaluation of the possibility to detect circulating tumor DNA from
405 pituitary adenoma. *Front Endocrinol (Lausanne)* **10**, 615 (2019).
- 406 2. Mouliere, F. *et al.* High fragmentation characterizes tumour-derived circulating
407 DNA. *PLoS ONE* **6**, e23418 (2011).
- 408 3. Jiang, P. & Lo, Y. M. D. The Long and Short of Circulating Cell-Free DNA and the
409 Ins and Outs of Molecular Diagnostics. *Trends Genet.* **32**, 360–371 (2016).
- 410 4. Heitzer, E. & Speicher, M. R. One size does not fit all: Size-based plasma DNA
411 diagnostics. *Sci. Transl. Med.* **10**, (2018).
- 412 5. Shen, S. Y. *et al.* Sensitive tumour detection and classification using plasma cell-
413 free DNA methylomes. *Nature* **563**, 579–583 (2018).
- 414 6. Kim, H., Wang, X. & Jin, P. Developing DNA methylation-based diagnostic
415 biomarkers. *J. Genet. Genomics* **45**, 87–97 (2018).
- 416 7. Wang, J. & Bettegowda, C. Applications of DNA-Based Liquid Biopsy for Central
417 Nervous System Neoplasms. *J. Mol. Diagn.* **19**, 24–34 (2017).
- 418 8. Best, M. G. *et al.* Liquid biopsies in patients with diffuse glioma. *Acta Neuropathol.*
419 **129**, 849–865 (2015).
- 420 9. Adamczyk, L. A. *et al.* Current Understanding of Circulating Tumor Cells - Potential
421 Value in Malignancies of the Central Nervous System. *Front. Neurol.* **6**, 174 (2015).
- 422 10. Saenz-Antoñanzas, A. *et al.* Liquid biopsy in glioblastoma: opportunities,
423 applications and challenges. *Cancers (Basel)* **11**, (2019).
- 424 11. Bos, M. K. *et al.* Whole exome sequencing of cell-free DNA - A systematic review
425 and Bayesian individual patient data meta-analysis. *Cancer Treat. Rev.* **83**, 101951
426 (2020).





- 427 12. Koepfel, F. *et al.* Whole exome sequencing for determination of tumor mutation
428 load in liquid biopsy from advanced cancer patients. *PLoS ONE* **12**, e0188174
429 (2017).
- 430 13. Neou, M. *et al.* Pangenomic classification of pituitary neuroendocrine tumors.
431 *Cancer Cell* (2019). doi:10.1016/j.ccell.2019.11.002
- 432 14. Bi, W. L. *et al.* Landscape of genomic alterations in pituitary adenomas. *Clin.*
433 *Cancer Res.* **23**, 1841–1851 (2017).
- 434 15. Song, Z.-J. *et al.* The genome-wide mutational landscape of pituitary adenomas.
435 *Cell Res.* **26**, 1255–1259 (2016).
- 436 16. Ling, C. *et al.* A pilot genome-scale profiling of DNA methylation in sporadic
437 pituitary macroadenomas: association with tumor invasion and histopathological
438 subtype. *PLoS ONE* **9**, e96178 (2014).
- 439 17. Kober, P. *et al.* DNA methylation profiling in nonfunctioning pituitary adenomas.
440 *Mol. Cell. Endocrinol.* **473**, 194–204 (2018).
- 441 18. Salomon, M. P. *et al.* The Epigenomic Landscape of Pituitary Adenomas Reveals
442 Specific Alterations and Differentiates Among Acromegaly, Cushing’s Disease and
443 Endocrine-Inactive Subtypes. *Clin. Cancer Res.* **24**, 4126–4136 (2018).
- 444 19. Duong, C. V. *et al.* Quantitative, genome-wide analysis of the DNA methylome in
445 sporadic pituitary adenomas. *Endocr. Relat. Cancer* **19**, 805–816 (2012).
- 446 20. Capper, D. *et al.* DNA methylation-based classification of central nervous system
447 tumours. *Nature* **555**, 469–474 (2018).
- 448 21. Gu, Y. *et al.* Differential DNA methylome profiling of nonfunctioning pituitary
449 adenomas suggesting tumour invasion is correlated with cell adhesion. *J*

- 450 *Neurooncol* **129**, 23–31 (2016).
- 451 22. Zhou, Y., Zhang, X. & Klibanski, A. Genetic and epigenetic mutations of tumor
452 suppressive genes in sporadic pituitary adenoma. *Mol. Cell. Endocrinol.* **386**, 16–33
453 (2014).
- 454 23. Torregrosa-Quesada, M. E. *et al.* How Valuable Is the RT-qPCR of Pituitary-
455 Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor
456 Subtypes According to the New WHO 2017 Criteria? *Cancers (Basel)* **11**, (2019).
- 457 24. Moran, S. *et al.* Epigenetic profiling to classify cancer of unknown primary: a
458 multicentre, retrospective analysis. *Lancet Oncol.* **17**, 1386–1395 (2016).
- 459 25. Hoadley, K. A. *et al.* Cell-of-Origin Patterns Dominate the Molecular Classification
460 of 10,000 Tumors from 33 Types of Cancer. *Cell* **173**, 291-304.e6 (2018).
- 461 26. Ceccarelli, M. *et al.* Molecular profiling reveals biologically discrete subsets and
462 pathways of progression in diffuse glioma. *Cell* **164**, 550–563 (2016).
- 463 27. Sahm, F. *et al.* DNA methylation-based classification and grading system for
464 meningioma: a multicentre, retrospective analysis. *Lancet Oncol.* **18**, 682–694
465 (2017).
- 466 28. Ferrareso, S. *et al.* DNA methylation profiling reveals common signatures of
467 tumorigenesis and defines epigenetic prognostic subtypes of canine Diffuse Large
468 B-cell Lymphoma. *Sci. Rep.* **7**, 11591 (2017).
- 469 29. Mosella, M. S. *et al.* DNA Methylation-based Signatures Classify Sporadic Pituitary
470 Tumors According to Clinicopathological Features. *BioRxiv* (2020).
471 doi:10.1101/2020.04.25.061903
- 472 30. Lokk, K. *et al.* DNA methylome profiling of human tissues identifies global and

- 473 tissue-specific methylation patterns. *Genome Biol.* **15**, r54 (2014).
- 474 31. Yang, X., Gao, L. & Zhang, S. Comparative pan-cancer DNA methylation analysis
475 reveals cancer common and specific patterns. *Brief. Bioinformatics* **18**, 761–773
476 (2017).
- 477 32. Hao, X. *et al.* DNA methylation markers for diagnosis and prognosis of common
478 cancers. *Proc Natl Acad Sci USA* **114**, 7414–7419 (2017).
- 479 33. Widschwendter, M. *et al.* Methylation patterns in serum DNA for early identification
480 of disseminated breast cancer. *Genome Med.* **9**, 115 (2017).
- 481 34. Constâncio, V. *et al.* Early detection of the major male cancer types in blood-based
482 liquid biopsies using a DNA methylation panel. *Clin. Epigenetics* **11**, 175 (2019).
- 483 35. Kang, S. *et al.* CancerLocator: non-invasive cancer diagnosis and tissue-of-origin
484 prediction using methylation profiles of cell-free DNA. *Genome Biol.* **18**, 53 (2017).
- 485 36. Noushmehr, H. *et al.* Detection of glioma and prognostic subtypes by non-invasive
486 circulating cell-free DNA methylation markers. *BioRxiv* (2019). doi:10.1101/601245
- 487 37. Mete, O. & Lopes, M. B. Overview of the 2017 WHO classification of pituitary
488 tumors. *Endocr. Pathol.* **28**, 228–243 (2017).
- 489 38. Raverot, G. *et al.* Risk of Recurrence in Pituitary Neuroendocrine Tumors: A
490 Prospective Study Using a Five-Tiered Classification. *J. Clin. Endocrinol. Metab.*
491 **102**, 3368–3374 (2017).
- 492 39. Fernández-Balsells, M. M. *et al.* Natural history of nonfunctioning pituitary
493 adenomas and incidentalomas: a systematic review and metaanalysis. *J. Clin.*
494 *Endocrinol. Metab.* **96**, 905–912 (2011).
- 495 40. Vasiljevic, A., Jouanneau, E., Trouillas, J. & Raverot, G. Clinicopathological

- 496 prognostic and theranostic markers in pituitary tumors. *Minerva Endocrinol.* **41**,
497 377–389 (2016).
- 498 41. Selman, W. R., Laws, E. R., Scheithauer, B. W. & Carpenter, S. M. The occurrence
499 of dural invasion in pituitary adenomas. *J. Neurosurg.* **64**, 402–407 (1986).
- 500 42. Asioli, S. *et al.* Validation of a clinicopathological score for the prediction of post-
501 surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from
502 a tertiary care centre. *Eur. J. Endocrinol.* **180**, 127–134 (2019).
- 503 43. Trouillas, J. *et al.* A new prognostic clinicopathological classification of pituitary
504 adenomas: a multicentric case-control study of 410 patients with 8 years post-
505 operative follow-up. *Acta Neuropathol.* **126**, 123–135 (2013).
- 506 44. Melmed, S. Pituitary-Tumor Endocrinopathies. *N. Engl. J. Med.* **382**, 937–950
507 (2020).
- 508 45. Nunes, S. P. *et al.* Subtyping lung cancer using DNA methylation in liquid biopsies.
509 *J. Clin. Med.* **8**, (2019).
- 510 46. Roy, D. & Tiirikainen, M. Diagnostic power of DNA methylation classifiers for early
511 detection of cancer. *Trends Cancer* **6**, 78–81 (2020).
- 512 47. Micko, A. S. G., Wöhrer, A., Wolfsberger, S. & Knosp, E. Invasion of the cavernous
513 sinus space in pituitary adenomas: endoscopic verification and its correlation with
514 an MRI-based classification. *J. Neurosurg.* **122**, 803–811 (2015).
- 515 48. Knosp, E., Steiner, E., Kitz, K. & Matula, C. Pituitary adenomas with invasion of the
516 cavernous sinus space: a magnetic resonance imaging classification compared
517 with surgical findings. *Neurosurgery* **33**, 610–7; discussion 617 (1993).
- 518 49. Gallardo-Gómez, M. *et al.* A new approach to epigenome-wide discovery of non-

- 519 invasive methylation biomarkers for colorectal cancer screening in circulating cell-
520 free DNA using pooled samples. *Clin. Epigenetics* **10**, 53 (2018).
- 521 50. Moss, J. *et al.* Comprehensive human cell-type methylation atlas reveals origins of
522 circulating cell-free DNA in health and disease. *Nat. Commun.* **9**, 5068 (2018).
- 523 51. Triche, T. J., Weisenberger, D. J., Van Den Berg, D., Laird, P. W. & Siegmund, K.
524 D. Low-level processing of Illumina Infinium DNA Methylation BeadArrays. *Nucleic*
525 *Acids Res.* **41**, e90 (2013).
- 526 52. Zhou, W., Laird, P. W. & Shen, H. Comprehensive characterization, annotation and
527 innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res.*
528 **45**, e22 (2017).
- 529 53. Gardiner-Garden, M. & Frommer, M. CpG islands in vertebrate genomes. *J. Mol.*
530 *Biol.* **196**, 261–282 (1987).
- 531 54. Sandoval, J. *et al.* Validation of a DNA methylation microarray for 450,000 CpG
532 sites in the human genome. *Epigenetics* **6**, 692–702 (2011).
- 533 55. Takai, D. & Jones, P. A. The CpG island searcher: a new WWW resource. *In Silico*
534 *Biol (Gedruckt)* **3**, 235–240 (2003).









Table 1- Summary of the clinicopathological features from patients harboring pituitary tumors and nontumor conditions (serum)

Feature	Nontumor (n=4)	NFPT (n=9)	FPT (n=4)
Gender			
Female	1	3	1
Male	2	6	3
Unknown	1	0	0
Age at surgery (years)			
Median (Lower and upper quartile)	31 (22-60)	65(57-68)	52(46-57)
2017 WHO/Hormone staining			
Gonadotroph/LH and/or FSH	-	4	-
Null Cell	-	5	-
Corticotroph/ACTH	-	-	1
Mixed/GH/PRL/TSH	-	-	1
Lactotroph/PRL	-	-	1
Densely lactotroph/PRL	-	-	1
Invasion status			
Invasive	-	5	2
Noninvasive	-	4	2
Size			
Micro_ <1cm	-	0	1
Macro_ ≥1-4cm	-	7	2
Giant_ ≥4cm	-	2	1

Legend - FPT: Functioning pituitary tumor. ACTH: Adrenocorticotropic hormone; GH: Growth hormone; PRL: prolactin; LH: luteinizing hormone; FSH: follicle stimulating hormone